A Pilot Study of 2% Tofacitinib Cream with Narrowband Ultraviolet B for the Treatment of Facial Vitiligo

    April 2019 in “ Journal of The American Academy of Dermatology ”
    Jacqueline McKesey, Amit G. Pandya
    New to Tofacitinib? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway. Our plain-language summary of this paper — not a Tressless recommendation.
    In 2019, a pilot study was conducted on 11 patients with facial vitiligo, testing a combination of 2% tofacitinib cream and narrowband ultraviolet B (NB-UVB) therapy for 3 ± 1 months. The patients, who had not responded to previous treatments, showed an average improvement of 70% in their Vitiligo Area Severity Index (VASI) scores. No side effects were reported. The study suggested that topical tofacitinib could be a beneficial addition to vitiligo treatment options, but acknowledged the limitations of a small sample size and lack of controls. The study recommended future controlled studies with larger sample sizes and long-term follow-up.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results